Advertisement
ABBV vs AMGN
Which Stock Would AI Choose? AbbVie (ABBV) vs. Amgen (AMGN) Stock Comparison
Key Takeaways
- ABBV reported stronger-than-expected Q2 2026 revenue growth of 10.2% year-over-year, driven by robust immunology product sales, though full-year earnings per share guidance was trimmed due to acquisition-related dilution.
- AMGN is scheduled to release Q2 2026 results on August 4, with analyst expectations centered on revenue of approximately $9.45 billion and earnings per share of $5.60, following consistent historical beats.
- ABBV maintains a larger market capitalization and a notable dividend yield, positioning it as a more income-oriented holding within the biotechnology sector compared to AMGN.
- Recent market activity shows ABBV experiencing post-earnings pressure on guidance adjustments, while AMGN trades ahead of its earnings catalyst amid broader sector stability.
- Both companies operate in the biotechnology space with overlapping exposure to immunology and oncology, yet differ in pipeline focus and capital allocation priorities.
- Relative performance over recent weeks highlights ABBV’s sales momentum offset by guidance concerns, contrasted with AMGN’s pre-earnings positioning.
Introduction
This comparison examines ABBV (AbbVie Inc.) and AMGN (Amgen Inc.), two leading biotechnology companies with significant presence in immunology and related therapeutic areas. The analysis focuses on recent financial results, stock price behavior, and market positioning to assist investors and traders evaluating sector exposure. Portfolio managers, income-focused investors, and those monitoring earnings catalysts may find the relative performance and business contrasts particularly relevant in the current environment.
ABBV Overview and Recent Performance
AbbVie Inc. develops and commercializes pharmaceutical products, with a primary emphasis on immunology treatments such as Skyrizi and Rinvoq. In recent weeks, the company delivered Q2 2026 revenue of $16.99 billion, representing a 10.2% year-over-year increase that exceeded analyst expectations, supported by strong Skyrizi sales growth of 24%. Despite the top-line strength, shares declined following the report as management lowered full-year 2026 adjusted earnings per share guidance to account for dilution from the planned Apogee Therapeutics acquisition. Market sentiment reflected a focus on the outlook revision amid otherwise solid operational performance.
AMGN Overview and Recent Performance
Amgen Inc. is a biotechnology company engaged in the discovery, development, and commercialization of human therapeutics, with key products spanning oncology, cardiovascular, and inflammation categories. Recent market activity for AMGN has centered on anticipation of its Q2 2026 earnings release scheduled for August 4. Analysts project revenue near $9.45 billion and earnings per share of $5.60, consistent with the company’s track record of beating estimates in prior quarters. Broader trading has remained relatively stable ahead of the report, with investors assessing potential updates on product growth and forward guidance.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of AI trading bots optimized for prevailing market conditions. Tickeron offers hundreds of AI Trading Bots that trade thousands of different tickers across various strategies, timeframes, and performance profiles. Only the highest-performing and most suitable bots for current conditions are featured in this trending section. Available bots display a range of win rates, profit factors, and drawdown statistics, allowing users to evaluate different trading styles and ticker combinations. The platform provides transparent metrics on each bot’s historical results and risk parameters. Explore the full selection on the Trending AI Robots page to identify options aligned with specific market views.
Head-to-Head Comparison
AbbVie and Amgen both operate within the biotechnology sector, yet differ in scale, dividend policy, and near-term catalysts. ABBV features a larger market capitalization and a higher dividend yield, appealing to income-oriented strategies, while AMGN emphasizes pipeline diversity and upcoming earnings visibility. Recent momentum for ABBV stems from immunology revenue strength, tempered by acquisition-related guidance adjustments, whereas AMGN positions ahead of its quarterly report without similar immediate overhang. Risk factors include regulatory and competitive pressures common to the sector, with ABBV showing greater recent sensitivity to forward-looking adjustments and AMGN carrying earnings surprise potential. Market sentiment reflects these trade-offs, with each stock offering distinct exposure profiles within the same industry.
Tickeron AI Verdict
Based on observable factors such as recent sales consistency, earnings reaction patterns, and relative positioning ahead of catalysts, Tickeron’s AI models currently assign a modestly higher probability of favorable near-term trend continuation to ABBV despite the guidance revision, given its demonstrated revenue momentum. AMGN presents a balanced profile centered on earnings delivery, which could shift relative assessments depending on outcomes. This assessment remains probabilistic and reflects data-driven pattern recognition rather than directional certainty.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Disclaimers and LimitationsTo compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABBV is a StrongBuy and AMGN is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABBV’s FA Score shows that 3 FA rating(s) are green whileAMGN’s FA Score has 4 green FA rating(s).
- ABBV’s FA Score: 3 green, 2 red.
- AMGN’s FA Score: 4 green, 1 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABBV’s TA Score shows that 4 TA indicator(s) are bullish while AMGN’s TA Score has 4 bullish TA indicator(s).
- ABBV’s TA Score: 4 bullish, 3 bearish.
- AMGN’s TA Score: 4 bullish, 4 bearish.
Price Growth
ABBV (@Pharmaceuticals: Major) experienced а +2.58% price change this week, while AMGN (@Pharmaceuticals: Major) price change was +6.23% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.89%. For the same industry, the average monthly price growth was -0.90%, and the average quarterly price growth was +1.95%.
Reported Earning Dates
ABBV is expected to report earnings on Oct 23, 2026.
AMGN is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+1.89% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| ABBV | AMGN | ABBV / AMGN | |
| Capitalization | 442B | 224B | 197% |
| EBITDA | 16.9B | 16.7B | 101% |
| Gain YTD | 12.041 | 28.417 | 42% |
| P/E Ratio | 70.65 | 25.73 | 275% |
| Revenue | 62.8B | 37.2B | 169% |
| Total Cash | N/A | 12B | - |
| Total Debt | 72.9B | 57.3B | 127% |
ABBV | AMGN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 76 | 32 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 44 Fair valued | 9 Undervalued | |
PROFIT vs RISK RATING 1..100 | 7 | 12 | |
SMR RATING 1..100 | 1 | 12 | |
PRICE GROWTH RATING 1..100 | 28 | 9 | |
P/E GROWTH RATING 1..100 | 80 | 39 | |
SEASONALITY SCORE 1..100 | 44 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AMGN's Valuation (9) in the Biotechnology industry is somewhat better than the same rating for ABBV (44) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew somewhat faster than ABBV’s over the last 12 months.
ABBV's Profit vs Risk Rating (7) in the Pharmaceuticals Major industry is in the same range as AMGN (12) in the Biotechnology industry. This means that ABBV’s stock grew similarly to AMGN’s over the last 12 months.
ABBV's SMR Rating (1) in the Pharmaceuticals Major industry is in the same range as AMGN (12) in the Biotechnology industry. This means that ABBV’s stock grew similarly to AMGN’s over the last 12 months.
AMGN's Price Growth Rating (9) in the Biotechnology industry is in the same range as ABBV (28) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to ABBV’s over the last 12 months.
AMGN's P/E Growth Rating (39) in the Biotechnology industry is somewhat better than the same rating for ABBV (80) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew somewhat faster than ABBV’s over the last 12 months.
| ABBV | AMGN | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 60% |
| Stochastic ODDS (%) | 2 days ago 70% | 2 days ago 52% |
| Momentum ODDS (%) | 2 days ago 37% | 2 days ago 58% |
| MACD ODDS (%) | 2 days ago 44% | 2 days ago 67% |
| TrendWeek ODDS (%) | 2 days ago 62% | 2 days ago 62% |
| TrendMonth ODDS (%) | 2 days ago 65% | 2 days ago 59% |
| Advances ODDS (%) | 2 days ago 60% | 8 days ago 59% |
| Declines ODDS (%) | 9 days ago 48% | 10 days ago 50% |
| BollingerBands ODDS (%) | 2 days ago 64% | 2 days ago 49% |
| Aroon ODDS (%) | 2 days ago 62% | 2 days ago 53% |
Advertisement
ABBV and
Correlation & Price change
A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with NVS. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then NVS could also see price increases.
| Ticker / NAME | Correlation To ABBV | 1D Price Change % | ||
|---|---|---|---|---|
| ABBV | 100% | +0.85% | ||
| NVS - ABBV | 52% Loosely correlated | -1.39% | ||
| BMY - ABBV | 50% Loosely correlated | -1.90% | ||
| JNJ - ABBV | 47% Loosely correlated | -0.77% | ||
| MRK - ABBV | 46% Loosely correlated | -0.38% | ||
| AMGN - ABBV | 46% Loosely correlated | -0.70% | ||
More | ||||